GlassScriptPhysician profile
Theresa Fynn
NPI 1669639266
$7,094.84
in general payments reported to CMS, 2019-2025
43 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,518 · 2020: $379 · 2021: $492 · 2022: $894 · 2023: $1,405 · 2024: $1,260 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,812.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,146.78 | 2021-2025 | Minimed 780g, Minimed 770g, Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $800.65 | 2019-2025 | |
| Novo Nordisk INC | $564.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $452.77 | 2022-2025 | |
| Amgen INC. | $376.56 | 2019-2025 | Evenity, Tepezza, Repatha |
| Lilly USA, LLC | $317.59 | 2019-2025 | Jardiance, Mounjaro, Lyumjev |
| Medtronic Minimed, INC. | $315.99 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.43 | 2019-2025 | Jardiance |
| Corcept Therapeutics | $245.51 | 2019-2025 | Korlym |
| Tandem Diabetes Care, INC. | $239.30 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $199.10 | 2019-2020 | |
| Dexcom, INC. | $152.11 | 2022-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $148.94 | 2019-2020 | |
| Insulet Corporation | $147.87 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $125.35 | 2021-2025 | Recorlev, Gvoke Hypopen |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $118.71 | 2022-2024 | |
| Renalytix Ai, INC. | $116.65 | 2022-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Horizon Therapeutics Plc | $99.09 | 2020-2022 | |
| Shire North American Group INC | $91.41 | 2019 | |
| Recordati_rare_diseases_inc. | $91.38 | 2025 | Isturisa |
| Amarin Pharma, INC. | $86.45 | 2019-2020 | |
| Mannkind Corporation | $82.39 | 2019 | |
| Madrigal Pharmaceuticals | $81.11 | 2025 | Rezdiffra |
| Ascendis Pharma Endocrinology INC | $68.26 | 2023-2025 | Yorvipath |
| Abbvie INC. | $65.63 | 2021-2024 | |
| Beta Bionics, INC. | $63.23 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Esperion Therapeutics, INC. | $62.43 | 2024-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.20 | 2019 | |
| Amneal Pharmaceuticals LLC | $52.67 | 2019-2024 | Unithroid |
| Amphastar Pharmaceuticals, INC. | $48.34 | 2024-2025 | |
| Ibsa Pharma INC. | $47.31 | 2022-2024 | Flector, Licart, Tirosint |
| Averitas Pharma INC. | $46.20 | 2023-2024 | Qutenza |
| Antares Pharma, INC. | $39.38 | 2019 | |
| Kyowa Kirin, INC. | $38.88 | 2024-2025 | Crysvita |
| Ascensia Diabetes Care US INC. | $29.77 | 2023 | |
| Sequel Med Tech, LLC | $28.92 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $26.47 | 2024 | |
| Merck Sharp & Dohme LLC | $22.85 | 2019 | |
| Enterra Medical, INC. | $22.81 | 2024 | |
| Astellas Pharma US INC | $22.05 | 2024 | Veozah |
| Ipsen Biopharmaceuticals, INC | $21.45 | 2019 | |
| Abbott Laboratories | $18.19 | 2024 | Freestyle Libre |
| Pfizer INC. | $16.56 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theresa Fynn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.